Status:
COMPLETED
Immune Monitoring in Sensitized Patients at Risk of Rejection
Lead Sponsor:
University of California, San Francisco
Conditions:
Kidney Failure
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to test the effect of anti-rejection medications on your immune system
Detailed Description
Recipients of deceased or living donor transplants with calculated percent reactive antibody (cPRA) of 50% or greater at University of California, San Francisco (UCSF) will be enrolled in the trial. S...
Eligibility Criteria
Inclusion
- 18 years or older able to consent
- No history of HIV, hepatitis C and active hepatitis B infection
- cPRA ≥ 50%
Exclusion
- Patients on Coumadin
- Human Leukocyte antigen (HLA) identical donor recipient patients
Key Trial Info
Start Date :
August 20 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 8 2017
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT03794817
Start Date
August 20 2015
End Date
September 8 2017
Last Update
January 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143